Medscape: New triplet regimen thought to boost melanoma survival, but at a cost
UC expert says more research on survival benefit needed
New research shows a combination therapy of three drugs for metastatic melanoma patients may provide significant survival benefits, but questions remain whether the regimen is cost effective.
Rekha Chaudhary, MD, adjunct associate professor at the UC College of Medicine and a UC Health oncologist, reviewed the research and said the triplet regimen makes sense for young and fit patients.
"However, this is a highly selected patient population," Chaudhary told Medscape. "There has been no overall survival benefit reported yet, so before we make final decisions, it would be nice to know if you really need all three drugs together at the same time or can you use them sequentially."
Chaudhary noted all three drugs are being used to treat metastatic melanoma currently in a sequential order, so she is skeptical if the cost effectiveness of the triplet regimen is an issue.
Featured photo at top of Dr. Chaudhary. Photo/Colleen Kelley/University of Cincinnati.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.